GeneDx Holdings Corp. (WGSWW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

GeneDx Holdings Corp. (WGSWW) Healthcare & Pipeline Overview

GeneDx Holdings Corp. offers genomics-related diagnostic services, leveraging its Centrellis AI platform to provide comprehensive health insights. Focusing on pediatrics, rare diseases, and hereditary cancer screening, the company operates within the competitive healthcare information services sector, facing challenges and opportunities in a rapidly evolving market.

What Is the Investment Thesis for WGSWW?

GeneDx Holdings Corp. presents a compelling investment case within the healthcare information services sector, driven by its Centrellis AI platform and focus on specialized genetic testing. The company's gross margin of 68.5% indicates strong pricing power and efficient operations. However, the negative profit margin of -4.9% and a high P/E ratio of -96.58 warrant careful consideration. Future growth will likely depend on expanding the adoption of Centrellis and penetrating key markets in pediatrics, rare diseases, and hereditary cancer screening. The company's high beta of 2.15 suggests significant volatility relative to the market. Investors should monitor the company's ability to achieve profitability and manage its operational costs effectively. The pending AI analysis could provide further insights into the company's technological capabilities and market potential.

Based on FMP financials and quantitative analysis

WGSWW Key Highlights

Gross Margin of 68.5% indicates strong pricing power in its diagnostic services.

• Focus on pediatrics, rare diseases, and hereditary cancer screening positions the company in high-demand areas of genetic testing.
• Centrellis AI platform provides a technological advantage in integrating and synthesizing clinical and genomic data.
• Negative Profit Margin of -4.9% highlights the need for improved operational efficiency.
• High Beta of 2.15 suggests significant volatility compared to the broader market.

Who Are WGSWW's Competitors?

WGSWW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are WGSWW's Key Strengths?

Proprietary Centrellis AI platform for advanced data analysis.

• Focus on high-growth areas like pediatrics and rare diseases.
• Strong gross margin indicates efficient operations.
• Expertise in genomics and genetic testing.

What Are WGSWW's Weaknesses?

Negative profit margin indicates operational inefficiencies.

• High beta suggests significant market volatility.
• Reliance on specific diagnostic areas may limit growth potential.
• Limited geographic reach compared to larger competitors.

What Could Drive WGSWW Stock Higher?

Expansion of Centrellis AI platform capabilities to include new diagnostic applications.

• Strategic partnerships with hospitals and research institutions to broaden data access and collaboration.
• Geographic expansion into emerging markets to increase customer base and revenue streams.

What Are the Key Risks for WGSWW?

Financial-distress signal — its Altman Z-Score of 1.65 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-38.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from established players in the healthcare information services industry.
• Rapid technological advancements may render existing solutions obsolete.
• Regulatory changes and reimbursement policies may impact revenue streams.
• Data privacy and security concerns may limit data access and collaboration.

What Are the Growth Opportunities for WGSWW?

• Expansion of Centrellis Platform: GeneDx can expand the capabilities of its Centrellis AI platform to include additional diagnostic applications and predictive analytics. The global AI in healthcare market is projected to reach $95 billion by 2030, offering a significant opportunity for growth. Timeline: Ongoing.
• Strategic Partnerships: Forming partnerships with hospitals, research institutions, and pharmaceutical companies can broaden GeneDx's reach and access to patient data. Collaborations can drive the development of new diagnostic tests and screening solutions. Timeline: Ongoing.
• Geographic Expansion: Expanding operations into new geographic markets, particularly in Europe and Asia, can increase GeneDx's customer base and revenue streams. The global genetic testing market is expected to reach $25 billion by 2028, with significant growth potential in emerging markets. Timeline: 2-3 years.
• Development of New Genetic Tests: Investing in the development of new genetic tests and screening solutions can address unmet needs in specific disease areas. Focus on rare diseases and personalized medicine can drive innovation and market differentiation. Timeline: 1-2 years.
• Increased Focus on Data Analytics: Leveraging the data generated by its diagnostic services to provide insights and analytics to healthcare providers and researchers. The market for healthcare analytics is expected to reach $75 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.

What Are WGSWW's Competitive Advantages?

• Proprietary Centrellis AI platform provides a competitive advantage in data analysis and health insights.
• Focus on specialized areas like pediatrics and rare diseases creates a niche market position.
• Strong relationships with hospitals and research institutions enhance data access and collaboration.
• Expertise in genomics and genetic testing provides a barrier to entry for new competitors.

What Does WGSWW Do?

GeneDx Holdings Corp., established in 2017 and headquartered in Stamford, Connecticut, operates as a provider of genomics-related diagnostic and information services. Through its subsidiaries, the company offers a range of genetic diagnostic tests, screening solutions, and information services. These services primarily focus on pediatrics, rare diseases affecting both children and adults, and hereditary cancer screening. At the core of GeneDx's offerings is Centrellis, an AI-driven health intelligence platform. Centrellis integrates digital tools and artificial intelligence, enabling scientists to ingest and synthesize clinical and genomic data. This integration facilitates the delivery of comprehensive health insights to healthcare professionals and patients. GeneDx aims to improve diagnostic accuracy and treatment strategies through advanced genomic analysis. The company's focus on AI-driven solutions and specialized diagnostic areas positions it within the evolving landscape of personalized medicine and healthcare information.

What Products and Services Does WGSWW Offer?

• Provides genetic diagnostic tests for various conditions.
• Offers screening solutions for pediatrics, rare diseases, and hereditary cancer.
• Develops and utilizes the Centrellis AI-driven health intelligence platform.
• Integrates digital tools and artificial intelligence for data analysis.
• Synthesizes clinical and genomic data to deliver health insights.
• Focuses on improving diagnostic accuracy and treatment strategies.

How Does WGSWW Make Money?

• Generates revenue through the sale of genetic diagnostic tests and screening services.
• Offers its Centrellis AI platform as a service to healthcare providers.
• Forms partnerships with hospitals and research institutions for data access and collaboration.

What Industry Does WGSWW Operate In?

GeneDx Holdings Corp. operates within the medical and healthcare information services industry, a sector experiencing rapid growth due to advancements in genomics and personalized medicine. The market is characterized by increasing demand for genetic testing and AI-driven diagnostic tools. Companies like BJDX, EUDA, GLMD, ISPC, and MLEC represent the competitive landscape. GeneDx's focus on specific areas like pediatrics and rare diseases allows it to carve out a niche in this competitive environment. The industry is driven by technological innovation and the need for more accurate and efficient diagnostic solutions.

Who Are WGSWW's Key Customers?

• Pediatricians and pediatric specialists.
• Oncologists and cancer centers.
• Individuals seeking genetic screening for hereditary conditions.
• Hospitals and healthcare systems.
• Research institutions and pharmaceutical companies.

GeneDx Holdings Corp. (WGSWW) Valuation Context

Relative to its peer group, WGSWW's quantitative score of 56/100 is roughly in line with the peer average of 52/100.

WGSWW Revenue & Earnings Trend

In Q2 2026, WGSWW generated $114.4M in top-line revenue, marking a sequential increase of 11.9%. The company recorded a net loss of $17.7M, with diluted EPS of $-0.60. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, WGSWW averaged $-0.91 in diluted EPS.

Company Profile

GeneDx Holdings Corp. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Katherine A. Stueland. WGSWW has traded publicly since 2021.

Return on equity for GeneDx Holdings Corp. stands at -38.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.5%, the inverse of the P/E and a quick read on earnings relative to price.

GeneDx Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.65 places it in the distress zone, a signal of elevated financial risk.

GeneDx Holdings Corp. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 93.2% below estimates on average.

Wall Street analysts project GeneDx Holdings Corp. revenue of about $478.4M for fiscal 2026, with EPS near $-0.06. The estimate reflects 10 contributing analysts.

Over the past six months, GeneDx Holdings Corp. insiders filed 29 SEC Form 4 transactions — 14 sales and 15 purchases. On net that is roughly 47K shares acquired (about $865K) — insiders putting money in tends to read as conviction.

WGSWW Financials

WGSWW Latest News

WGSWW Analyst Consensus

WGSWW MoonshotScore

What Investors Ask About GeneDx Holdings Corp. (WGSWW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources